CN117942367A - Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury - Google Patents
Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury Download PDFInfo
- Publication number
- CN117942367A CN117942367A CN202311772251.7A CN202311772251A CN117942367A CN 117942367 A CN117942367 A CN 117942367A CN 202311772251 A CN202311772251 A CN 202311772251A CN 117942367 A CN117942367 A CN 117942367A
- Authority
- CN
- China
- Prior art keywords
- preparation
- parts
- water
- pinocembrin
- ischemic injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- RTIXKCRFFJGDFG-UHFFFAOYSA-N Chrysin Natural products C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 title claims abstract description 56
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 title claims abstract description 56
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 title claims abstract description 56
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 title claims abstract description 56
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 37
- 208000037906 ischaemic injury Diseases 0.000 title claims abstract description 37
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims abstract description 22
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims abstract description 22
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 238000010298 pulverizing process Methods 0.000 claims abstract description 9
- 241000427159 Achyranthes Species 0.000 claims abstract description 8
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 8
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 8
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 8
- 241000628997 Flos Species 0.000 claims abstract description 8
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract 3
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 18
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- 238000002791 soaking Methods 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 241000241413 Propolis Species 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010829 isocratic elution Methods 0.000 claims description 9
- 229940069949 propolis Drugs 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000002953 preparative HPLC Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- HJBWJAPEBGSQPR-GQCTYLIASA-N 3,4-dimethoxycinnamic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1OC HJBWJAPEBGSQPR-GQCTYLIASA-N 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- HJBWJAPEBGSQPR-UHFFFAOYSA-N DMCA Natural products COC1=CC=C(C=CC(O)=O)C=C1OC HJBWJAPEBGSQPR-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- FBUBVLUPUDBFME-UHFFFAOYSA-N Xanthoxylin Chemical compound COC1=CC(O)=C(C(C)=O)C(OC)=C1 FBUBVLUPUDBFME-UHFFFAOYSA-N 0.000 abstract description 6
- 229930189533 tanshinol Natural products 0.000 abstract description 4
- FXVRSKPFWVYCPN-UHFFFAOYSA-N brevifolin Natural products OC1=C(O)C(O)=CC(C(O2)=O)=C1C1=C2C(=O)CC1 FXVRSKPFWVYCPN-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 6
- 241000723353 Chrysanthemum Species 0.000 description 5
- 241001106477 Paeoniaceae Species 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of application of pinocembrin, and discloses application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury, wherein 10 parts of pinocembrin, 6 parts of salvianic acid A, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach kernel, 7 parts of chrysanthemum, 6 parts of poria cocos, 4 parts of achyranthes and 3 parts of bitter orange are weighed according to parts by weight; mixing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, semen Persicae, flos Chrysanthemi, poria, achyranthis radix, fructus Aurantii, pulverizing into powder, and mixing with pinocembrin and tanshinol to obtain preparation for preventing cerebral ischemic injury. The pinocembrin prepared by the preparation method of pinocembrin has high purity, so that the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury is greatly improved; meanwhile, the quality of the salvianic acid A prepared by the salvianic acid A preparation method is high, so that the quality of the application of the brevifolin in preparing the preparation for preventing cerebral ischemic injury is greatly improved.
Description
Technical Field
The invention belongs to the technical field of application of pinocembrin, and particularly relates to application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury.
Background
The cerebrovascular diseases have the characteristics of high disability rate, high death rate and high recurrence rate, the severe omeiensis threatens the life health and the life quality of human beings, the cerebrovascular diseases occupy the first place of death causes of urban and rural residents in China, account for 22.45 percent of the total death number, and are diseases with single diseases and highest disability rate, thus becoming serious public health problems. In China, cerebral infarction accounts for about 70% of cerebrovascular diseases, the medical cost for treating the cerebrovascular diseases per year is up to 1400 hundred million yuan, and the cerebral infarction brings heavy burden to families and society. Therefore, importance is attached to the prevention and treatment of cerebral infarction, and the method has extremely important significance for the whole society. A series of pathophysiological lesions are caused after acute cerebral ischemia: stopping synthesis of neuron protein, depolarizing, increasing calcium ion inflow, releasing excitatory amino acid in large quantity, etc., resulting in overload of intracellular calcium, increased generation of oxygen free radical, change of mitochondrial function, inducing apoptosis of neuron, etc. At present, in the research of medicines for treating cerebral ischemia, two strategies are mainly based, namely, the development of neuroprotectants aiming at protecting nerve cell functions aims at protecting and recovering nerve functions in ischemic areas by blocking cascade reactions of nerve cell death through medicines; secondly, it is desirable to restore blood supply to the ischemic area of the brain by revascularization, dilation or revascularization. The medicine for improving blood supply is more commonly used in clinic at present: for example r-tPA, which has excellent thrombolytic effect, but this drug application has strict time window limitations, and early ischemic stroke blood brain barrier disruption is an important pathophysiological basis leading to ischemia reperfusion injury, angiogenic cerebral edema and hemorrhagic transformation. The neuroprotectant is based on the intervention of cytopathology biochemical cascade, and can reduce ischemic brain injury by reducing intracellular calcium overload, antagonizing excitatory amino acid toxicity, scavenging oxygen free radicals, inhibiting inflammatory reaction and other ways, and promote the recovery of nerve function. Although NMDA receptor antagonists may block NMDA receptor mediated neuronal death or apoptosis, inhibiting neuronal excitotoxicity. NMDA receptor antagonists, however, do not perform well in clinical trials because, when administered to patients with acute cerebral ischemia, higher doses tend to cause hypertension, dysmnesia and even conversely neurotoxicity to accelerate patient death: however, too low a dose does not provide neuroprotection, and the above drawbacks limit the use of NMDA receptor antagonists as therapeutic agents for cerebral ischemia.
Studies show that pinocembrin can reduce nerve cell injury caused by oxygen glucose deprivation and has neuroprotective effect. The pinocembrin can antagonize intracellular calcium overload, reduce oxidative stress injury, nerve cell apoptosis and other links, and prevent ischemia reperfusion injury. The raw material pinocembrin adopted by the prior application of pinocembrin in preparation of preparations for preventing cerebral ischemic injury contains impurities, which influence the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury; meanwhile, in the preparation of the compound preparation, the quality of the adopted raw material salvianic acid A is poor, and the application quality of the pinocembrin in the preparation of the preparation for preventing cerebral ischemic injury is influenced.
Through the above analysis, the problems and defects existing in the prior art are as follows:
(1) The raw material pinocembrin adopted by the prior application of pinocembrin in preparation of preparations for preventing cerebral ischemic injury contains impurities, which influence the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury.
(2) The quality difference of the adopted raw material salvianic acid A affects the application quality of the pinocembrin in preparation of the preparation for preventing cerebral ischemic injury.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides an application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury.
The invention is realized in that the application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury is characterized by comprising the following steps:
Weighing 10 parts of pinocembrin, 6 parts of danshensu, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root, 3 parts of bitter orange and 2 parts of phosphatidylcholine according to parts by weight;
Soaking peach kernels in boiled water, and soaking for 1 to 2 hours with a small amount of edible salt; soaking semen Persicae in hot water for 50 min, removing skin of semen Persicae, soaking semen Persicae in saline water for half an hour to whiten semen Persicae, and oven drying at low temperature;
Pulverizing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, flos Chrysanthemi, poria, achyranthis radix, and fructus Aurantii separately, and adjusting the pulverizing granularity;
and thirdly, mixing the processed peach kernels, red paeony root, szechuan lovage rhizome, chinese angelica, safflower, chrysanthemum, indian buead, twotooth achyranthes root, bitter orange, pinocembrin, danshensu and a newly added neuroprotectant to prepare the preparation for preventing cerebral ischemic injury.
Further, the low-temperature drying removes moisture in the substance under the conditions of low temperature and reduced pressure:
Pumping air in the device by using a vacuum pump, creating a vacuum environment in the drying device, wherein water molecules in the substance are easier to evaporate due to the pressure reduction; in the whole process, a certain amount of heat is continuously supplied to the substance, and the heat is transmitted to the substance by radiation and convection from a heating system of the equipment; the moisture will change from liquid to gas after obtaining enough heat and then be separated from the substance; the separated water vapor is pumped by a vacuum pump.
Further, the preparation method of the pinocembrin comprises the following steps:
(1) Extracting propolis with purified water and edible alcohol at different ratio, separating solid from liquid, mixing filtrates, and regulating the content of effective components to standard requirement to obtain qualified water-soluble propolis extract; freezing propolis, pulverizing, extracting with distilled water under heating, filtering, naturally cooling the water extractive solution to room temperature, removing the upper coagulated Cera flava, and concentrating the lower aqueous solution under reduced pressure to relative density of about 1.2;
(2) Adding 96% ethanol to the concentrated solution until the ethanol content is about 75%, standing overnight, collecting supernatant, and concentrating to obtain extract; coarse separation of macroporous adsorption resin: dissolving the extract with appropriate amount of water, loading onto macroporous adsorbent resin column, eluting with water, and sequentially eluting with 25%, 45%, 65%, 85%, 96% ethanol-water solution as mobile phase gradient; collecting 45% and 65% ethanol eluting parts respectively, and concentrating to obtain a sample;
(3) Semi-preparative high performance liquid chromatography separation and purification of samples: separating and purifying the sample by semi-preparative high performance liquid chromatography, wherein the chromatographic column is C18SMB100 column, the mobile phase is methanol-water, and the ratio of 50:50, V/V, detecting the wavelength to be 280nm, collecting the fraction of the target component, and concentrating the obtained fraction under reduced pressure to obtain the monomer compounds 3, 4-dimethoxy cinnamic acid and pinocembrin to be separated.
Further, the heat extraction time was 3 hours.
Further, the number of extraction times was 7.
Further, the distilled water is used in an amount of 11 times during the heating extraction;
the separation and purification are performed by using methanol-water eluent, wherein the elution modes comprise methanol-water gradient elution, 55% methanol-water isocratic elution, 50% methanol-water isocratic elution and 45% methanol-water isocratic elution.
Further, the preparation method of the tanshinol comprises the following steps:
1) Slicing Saviae Miltiorrhizae radix, and extracting with alkaline water solution with pH of 7 at 86 deg.C to obtain extract containing salvianic acid A; adjusting pH of the extractive solution to 5 with acid, and filtering to remove precipitate; concentrating the supernatant at 66 ℃; precipitating the concentrated solution with ethanol to reach ethanol concentration of 87%, standing, removing precipitate, and concentrating the filtrate at 76deg.C until no ethanol smell;
2) Loading the concentrated solution on a macroporous adsorption resin column, eluting with water with the volume of 5 times of the resin volume, discarding, eluting with water with the volume of 6 times of the resin volume, and collecting the eluent; concentrating the eluent at 78 ℃, regulating the pH to 8 by alkaline water, and freeze-drying to obtain solid; dissolving the above solid with ethanol under heating, filtering, cooling, concentrating the filtrate at low temperature to small volume, and crystallizing to obtain high purity salvianic acid A with content of more than 93%.
Further, the alkaline water used for the extraction is sodium hydroxide, potassium hydroxide or ammonia water.
Further, the extraction times of the hot dipping method are 5 times, the dosage of alkaline water is 17 times of the weight of the red sage root medicine, and the extraction time of each time is 3 hours.
Further, the acid is hydrochloric acid, acetic acid or sulfuric acid.
Further, the ethanol is absolute ethanol or 95% ethanol.
In combination with the technical scheme and the technical problems to be solved, the technical scheme to be protected has the following advantages and positive effects:
First, the present invention has increased the neuroprotective agent phosphatidylcholine, a substance that has been shown to protect nerve cells, reduce oxidative stress, and improve nerve cell function, thereby enhancing the prophylactic effect of the agent on ischemic brain injury. Secondly, by separately crushing each raw material, the property of each medicine can be expressed under the optimal granularity, which is beneficial to the efficacy exertion of the medicine. Finally, by changing the treatment method of the peach kernel, low-temperature drying is used for replacing high-pressure cooking, active ingredients of the peach kernel can be better preserved, and the overall effect of the medicament is improved.
Secondly, the purity of the pinocembrin prepared by the preparation method of the pinocembrin is high, so that the application quality of the pinocembrin in preparation of preparations for preventing cerebral ischemic injury is greatly improved; meanwhile, the quality of the salvianic acid A prepared by the salvianic acid A preparation method is high, so that the quality of the application of the brevifolin in preparing the preparation for preventing cerebral ischemic injury is greatly improved.
Drawings
Fig. 1 is a flowchart of application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury, which is provided by the embodiment of the invention.
Fig. 2 is a flowchart of a preparation method of pinocembrin according to an embodiment of the present invention.
Fig. 3 is a flowchart of a preparation method of tanshinol according to an embodiment of the present invention.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
As shown in fig. 1, the invention provides an application method of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury, which comprises the following steps:
S101, weighing 10 parts of pinocembrin, 6 parts of salvianic acid A, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root and 3 parts of bitter orange according to parts by weight;
the peach kernel treatment method comprises the following steps:
Soaking semen Persicae in boiled water, wherein the soaking time is 1-2 hr;
Soaking semen Persicae in hot water for 50 min, removing skin of semen Persicae, soaking semen Persicae in saline water for half an hour to whiten semen Persicae, and sterilizing by steaming semen Persicae under high pressure;
S102, mixing and crushing red paeony root, szechuan lovage rhizome, chinese angelica, safflower, peach seed, chrysanthemum, indian buead, twotooth achyranthes root and bitter orange into powder, and then mixing with pinocembrin and danshensu to prepare the preparation for preventing cerebral ischemic injury.
As shown in fig. 2, the preparation method of pinocembrin provided by the invention comprises the following steps:
S201, extracting propolis with purified water and edible alcohol according to different proportions, mixing filtrates after solid-liquid separation, and adjusting the content of effective components to standard requirements to obtain qualified water-soluble propolis extract; freezing propolis, pulverizing, extracting with distilled water under heating, filtering, naturally cooling the water extractive solution to room temperature, removing the upper coagulated Cera flava, and concentrating the lower aqueous solution under reduced pressure to relative density of about 1.2;
S202, adding 96% ethanol into the concentrated solution until the ethanol content is about 75%, standing overnight, and concentrating the supernatant to obtain an extract; coarse separation of macroporous adsorption resin: dissolving the extract with appropriate amount of water, loading onto macroporous adsorbent resin column, eluting with water, and sequentially eluting with 25%, 45%, 65%, 85%, 96% ethanol-water solution as mobile phase gradient; collecting 45% and 65% ethanol eluting parts respectively, and concentrating to obtain a sample;
S203, semi-preparative high performance liquid chromatography separation and purification of the sample: separating and purifying the sample by semi-preparative high performance liquid chromatography, wherein the chromatographic column is C18SMB100 column, the mobile phase is methanol-water, and the ratio of 50:50, V/V, detecting the wavelength to be 280nm, collecting the fraction of the target component, and concentrating the obtained fraction under reduced pressure to obtain the monomer compounds 3, 4-dimethoxy cinnamic acid and pinocembrin to be separated.
The heating extraction time provided by the invention is 3 hours.
The extraction times provided by the invention are 7 times.
The distilled water consumption is 11 times of the distilled water consumption during heating extraction;
the separation and purification are performed by using methanol-water eluent, wherein the elution modes comprise methanol-water gradient elution, 55% methanol-water isocratic elution, 50% methanol-water isocratic elution and 45% methanol-water isocratic elution.
As shown in FIG 3, the preparation method of the salvianic acid A provided by the invention comprises the following steps:
S301, slicing the red sage root medicinal material, and extracting by adopting an alkaline aqueous solution hot dipping method with the pH value of 7 at 86 ℃ to obtain an extract containing tanshinol; adjusting pH of the extractive solution to 5 with acid, and filtering to remove precipitate; concentrating the supernatant at 66 ℃; precipitating the concentrated solution with ethanol to reach ethanol concentration of 87%, standing, removing precipitate, and concentrating the filtrate at 76deg.C until no ethanol smell;
s302, loading the concentrated solution on a macroporous adsorption resin column, eluting with water with the volume of 5 times of the resin volume, discarding, continuing eluting with water with the volume of 6 times of the resin volume, and collecting the eluent; concentrating the eluent at 78 ℃, regulating the pH to 8 by alkaline water, and freeze-drying to obtain solid; dissolving the above solid with ethanol under heating, filtering, cooling, concentrating the filtrate at low temperature to small volume, and crystallizing to obtain high purity salvianic acid A with content of more than 93%.
The alkaline water used for extraction provided by the invention is sodium hydroxide, potassium hydroxide or ammonia water.
The hot dipping method provided by the invention has the extraction times of 5 times, the dosage of alkaline water is 17 times of the weight of the salvia miltiorrhiza medicinal material, and the extraction time of each time is 3 hours.
The acid provided by the invention is hydrochloric acid, acetic acid or sulfuric acid.
The ethanol provided by the invention is absolute ethanol or 95% ethanol.
The pinocembrin prepared by the preparation method of pinocembrin has high purity, so that the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury is greatly improved; meanwhile, the quality of the salvianic acid A prepared by the salvianic acid A preparation method is high, so that the quality of the application of the brevifolin in preparing the preparation for preventing cerebral ischemic injury is greatly improved.
Four practical application cases of the embodiment of the invention are as follows:
embodiment one: preparation of pharmaceutical formulations
Weighing 10 parts of pinocembrin, 6 parts of danshensu, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root, 3 parts of bitter orange and 2 parts of phosphatidylcholine according to the weight parts.
Soaking semen Persicae in boiled water containing appropriate amount of edible salt for 1-2 hr, soaking in hot water for 50 min, peeling, soaking semen Persicae in salt water for half an hour to whiten, and oven drying at low temperature.
Pulverizing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, flos Chrysanthemi, poria, achyranthis radix, and fructus Aurantii respectively into powder.
Finally, all the raw materials are mixed to prepare the preparation for preventing cerebral ischemic injury.
Embodiment two: preventing and treating senile people suffering from hypertension for a long time
The patient is given the appropriate amount of the formulation according to the order twice daily. Patients need to monitor blood pressure regularly throughout the course of treatment, taking care of changes in diet and lifestyle. After 3 months of preventive use, the blood pressure of the patient is stable, and symptoms such as dizziness and headache are obviously improved.
Embodiment III: post-operative cerebral ischemic injury prevention
For patients who are about to undergo large-scale surgery, the preparation is administered before the surgery for preventive treatment, and the preparation is continuously used after the surgery to strengthen the protection of cerebral ischemic injury. The recovery status of the patient is continuously observed, and the dosage and the frequency of the drug use are adjusted.
The foregoing is merely illustrative of specific embodiments of the present invention, and the scope of the invention is not limited thereto, but any modifications, equivalents, improvements and alternatives falling within the spirit and principles of the present invention will be apparent to those skilled in the art within the scope of the present invention.
Claims (10)
1. Use of pinocembrin in the preparation of a formulation for preventing cerebral ischemic injury comprising:
Weighing 10 parts of pinocembrin, 6 parts of danshensu, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root, 3 parts of bitter orange and 2 parts of phosphatidylcholine according to parts by weight;
Soaking peach kernels in boiled water, and soaking for 1 to 2 hours with a small amount of edible salt; soaking semen Persicae in hot water for 50 min, removing skin of semen Persicae, soaking semen Persicae in saline water for half an hour to whiten semen Persicae, and oven drying at low temperature;
Pulverizing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, flos Chrysanthemi, poria, achyranthis radix, and fructus Aurantii separately, and adjusting the pulverizing granularity;
and thirdly, mixing the processed peach kernels, red paeony root, szechuan lovage rhizome, chinese angelica, safflower, chrysanthemum, indian buead, twotooth achyranthes root, bitter orange, pinocembrin, danshensu and a newly added neuroprotectant to prepare the preparation for preventing cerebral ischemic injury.
2. Use of pinocembrin according to claim 1 for the preparation of a formulation for preventing cerebral ischemic injury, wherein the low temperature drying removes water from the material under low temperature and reduced pressure conditions:
Pumping air in the device by using a vacuum pump, creating a vacuum environment in the drying device, wherein water molecules in the substance are easier to evaporate due to the pressure reduction; in the whole process, a certain amount of heat is continuously supplied to the substance, and the heat is transmitted to the substance by radiation and convection from a heating system of the equipment; the moisture will change from liquid to gas after obtaining enough heat and then be separated from the substance; the separated water vapor is pumped by a vacuum pump.
3. Use of pinocembrin according to claim 1 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the pinocembrin is prepared by the following method:
(1) Extracting propolis with purified water and edible alcohol at different ratio, separating solid from liquid, mixing filtrates, and regulating the content of effective components to standard requirement to obtain qualified water-soluble propolis extract; freezing propolis, pulverizing, extracting with distilled water under heating, filtering, naturally cooling the water extractive solution to room temperature, removing the upper coagulated Cera flava, and concentrating the lower aqueous solution under reduced pressure to relative density of about 1.2;
(2) Adding 96% ethanol to the concentrated solution until the ethanol content is about 75%, standing overnight, collecting supernatant, and concentrating to obtain extract; coarse separation of macroporous adsorption resin: dissolving the extract with appropriate amount of water, loading onto macroporous adsorbent resin column, eluting with water, and sequentially eluting with 25%, 45%, 65%, 85%, 96% ethanol-water solution as mobile phase gradient; collecting 45% and 65% ethanol eluting parts respectively, and concentrating to obtain a sample;
(3) Semi-preparative high performance liquid chromatography separation and purification of samples: separating and purifying the sample by semi-preparative high performance liquid chromatography, wherein the chromatographic column is C18SMB100 column, the mobile phase is methanol-water, and the ratio of 50:50, V/V, detecting the wavelength to be 280nm, collecting the fraction of the target component, and concentrating the obtained fraction under reduced pressure to obtain the monomer compounds 3, 4-dimethoxy cinnamic acid and pinocembrin to be separated.
4. Use of pinocembrin according to claim 3 for the preparation of a formulation for the prevention of cerebral ischemic injury, wherein the heat extraction time is 3 hours;
The number of extraction times was 7.
5. The use of pinocembrin according to claim 3 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the distilled water is used in an amount of 11 times during the heat extraction;
the separation and purification are performed by using methanol-water eluent, wherein the elution modes comprise methanol-water gradient elution, 55% methanol-water isocratic elution, 50% methanol-water isocratic elution and 45% methanol-water isocratic elution.
6. The use of pinocembrin according to claim 1 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the preparation method of pinocembrin comprises the following steps:
1) Slicing Saviae Miltiorrhizae radix, and extracting with alkaline water solution with pH of 7 at 86 deg.C to obtain extract containing salvianic acid A; adjusting pH of the extractive solution to 5 with acid, and filtering to remove precipitate; concentrating the supernatant at 66 ℃; precipitating the concentrated solution with ethanol to reach ethanol concentration of 87%, standing, removing precipitate, and concentrating the filtrate at 76deg.C until no ethanol smell;
2) Loading the concentrated solution on a macroporous adsorption resin column, eluting with water with the volume of 5 times of the resin volume, discarding, eluting with water with the volume of 6 times of the resin volume, and collecting the eluent; concentrating the eluent at 78 ℃, regulating the pH to 8 by alkaline water, and freeze-drying to obtain solid; dissolving the above solid with ethanol under heating, filtering, cooling, concentrating the filtrate at low temperature to small volume, and crystallizing to obtain high purity salvianic acid A with content of more than 93%.
7. The use of pinocembrin according to claim 6 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the alkaline water used for the extraction is sodium hydroxide, potassium hydroxide or ammonia water.
8. The use of pinocembrin according to claim 6 for preparing preparation for preventing cerebral ischemic injury, wherein the extraction times by hot dipping method is 5 times, the alkaline water amount is 17 times of the weight of the radix Salviae Miltiorrhizae, and the extraction time is 3 hours each time.
9. Use of pinocembrin according to claim 6 for the preparation of a formulation for the prevention of cerebral ischemic injury, wherein the acid is hydrochloric acid, acetic acid or sulfuric acid.
10. The use of pinocembrin according to claim 6 for the preparation of a formulation for preventing cerebral ischemic injury, wherein the ethanol is absolute ethanol or 95% ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311772251.7A CN117942367A (en) | 2023-12-21 | 2023-12-21 | Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311772251.7A CN117942367A (en) | 2023-12-21 | 2023-12-21 | Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117942367A true CN117942367A (en) | 2024-04-30 |
Family
ID=90795612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311772251.7A Pending CN117942367A (en) | 2023-12-21 | 2023-12-21 | Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117942367A (en) |
-
2023
- 2023-12-21 CN CN202311772251.7A patent/CN117942367A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| AU2003242135A1 (en) | Preparation Method of Danshentotalphenolic Acid and the Use Thereof | |
| CN102119964A (en) | Extract of preventing and treating coronary heart disease and stenocardia and preparation method and application thereof | |
| Wu et al. | Preparation of paeoniflorin from the stems and leaves of Paeonia lactiflora Pall.‘Zhongjiang’through green efficient microwave-assisted extraction and subcritical water extraction | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN106432385A (en) | Preparation method for high-purity breviscapine extract as well as preparations and application thereof | |
| CN117942367A (en) | Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury | |
| CN112107639B (en) | Application of fructus viticis extract in preparation of antidepressant drugs | |
| CN109172637B (en) | Preparation method of capsule for treating rheumatism | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| CN1256134C (en) | Medicinal composition for treating rheumatoid | |
| CN104116753B (en) | The application of aucubin in preparation treatment idiopathic pulmonary fibrosis medicine | |
| CN102895386B (en) | Method for performing extraction on angelica dahurica, common cnidium fruit, Chinese red pepper and elecampane inula root and pharmaceutical application | |
| CN112546085A (en) | Sambucus chinensis extract for treating gout and preparation method thereof | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1319546C (en) | Delayed-releasing preparation for treating osteoporosis | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
| CN114028526B (en) | A pharmaceutical composition for treating gastric precancerous lesion and gastric cancer, and its preparation method | |
| CN111759891B (en) | Pharmaceutical composition for treating myocardial ischemia and application thereof | |
| CN114748440B (en) | Astragalus glue capsule composition for increasing white and its preparing method and use | |
| CN107582747B (en) | Preparation method of Jinma Gantai preparation | |
| CN1123683A (en) | Series products of radix notoginseng and cortex eucommiae and their productions | |
| CN1876128A (en) | A medicine for treating metrorrhagia and preparation process thereof | |
| CN1283303C (en) | Medicine composition for ischemia apoplexy | |
| CN117503856A (en) | Application of plant essential oil in preparation of medicine or health product for treating hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |